Synapse - Gregory Riely

Results (121)

MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition

Meeting Abstract

Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Utility of cfDNA testing for acquired resistance: The Memorial Sloan Kettering experience with plasma EGFR T790M clinical testing

Meeting Abstract

Offin, M.; Myers, M.; Josyula, S.; Shen, R.; Borsu, L.; Tsui, D.; Riely, G.; Rudin, C.; Yu, H.; Li, B.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB

Meeting Abstract

Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers

Journal Article

Sabari, J. K.; Leonardi, G. C.; Shu, C. A.; Umeton, R.; Montecalvo, J.; Ni, A.; Chen, R.; Dienstag, J.; Mrad, C.; Bergagnini, I.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial

Journal Article

Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers

Journal Article

Drilon, A.; Lin, J. J.; Filleron, T.; Ni, A.; Milia, J.; Bergagnini, I.; Hatzoglou, V.; Velcheti, V.; Offin, M.; Li, B.; more...
Journal of Thoracic Oncology (2018)

Fulltext@MSK | Save

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer

Journal Article

Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W. V.; Hendriks, L. E. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance

Journal Article

Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
Clinical Cancer Research (2018)

Fulltext@MSK | Save

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing